Revenue segments as reported by the company.

Nutrition

Diagnostics

Established Pharmaceuticals

Medical Devices

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Amortization of intangible assets

Research and development

Selling, general, and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Abbott Labs

St. Jude Medical was an American global medical device company headquartered in Little Canada, Minnesota, U.S., a suburb of Saint Paul. The company had more than 20 principal operations and manufacturing facilities worldwide with products sold in more than 100 countries. The company was acquired by Abbott Laboratories in January 2017.

St. Jude Medical

Abbott Laboratories engages in the discovery, development, manufacture, and sale of health care products. It operates through the following business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The Established Pharmaceutical Products segment refers to the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment markets diagnostic systems and tests for blood banks, hospitals, commercial laboratories, and alternate-care testing sites. The Nutritional Products segment caters to the worldwide sales of adult and pediatric nutritional products. The Medical Devices segment includes electrophysiology, heart failure, vascular and structural heart devices for the treatment of cardiovascular diseases, and diabetes care products for people with diabetes, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company was founded by Wallace Calvin Abbott in 1888 and is headquartered in Abbott Park, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Abbott Labs reports solid Q4 performance and eyes growth opportunities

Abbott Labs delivered a strong performance in Q4 2022, showcasing resilience and strategic focus amidst challenges in certain business segments.
The company's emphasis on innovation, product excellence, and market expansion positions it well for future growth and success.
While facing challenges like inflation and market restrictions, Abbott is actively pursuing opportunities for growth through new product launches and strategic investments.
Investors can be optimistic about Abbott's outlook for 2023, with a positive trajectory in sales, product development, and cash use priorities.

Abbott Labs surpasses Q1 earnings estimates, eyes growth opportunities

Abbott Labs exceeded earnings expectations with strong organic sales growth. Performance driven by Medical Devices, Established Pharmaceuticals, and Nutrition segments. Challenges include lower Diagnostics sales and uncertainties around COVID testing.

Abbott Labs excels in Q2 with strong sales growth and innovation

Abbott Labs delivered a strong performance in Q2 2023, driven by robust organic sales growth, successful product launches, and strategic market expansion initiatives across key business segments.
Despite challenges related to COVID testing demand decline and exchange rate impacts, Abbott's focus on innovation, market share recovery, and operational efficiency positions it well for sustained growth and profitability.
The company's strengths in diverse product offerings, market leadership in key segments, and opportunities for further expansion and innovation underscore its resilience and strategic vision in the healthcare industry.
By navigating challenges, leveraging strengths, and capitalizing on opportunities, Abbott is poised to maintain its growth trajectory, drive market leadership, and deliver value to shareholders and stakeholders.

Abbott Labs excels in Q3, eyes growth in China and innovation

Abbott Labs delivered robust performance across key segments, positioning well for sustained growth.
The company showcased strong sales growth, user adoption, and strategic readiness for future opportunities.
While challenges exist in market dynamics and cost management, Abbott remains optimistic about its outlook.
Overall, Abbott's Q3 results reflect a resilient business model and a focus on innovation and growth.

Abbott Labs surpasses 2023 expectations, poised for strong 2024 growth

Abbott Labs delivered impressive performance in 2023, exceeding expectations and showcasing strength across key segments. The company's diversified business model and strategic investments position it well for continued growth in 2024. Abbott's focus on sustainable growth, market share expansion, and innovation bode well for its future.

Abbott Labs excels in Q1, raises guidance on strong performance

Abbott Labs delivered a standout quarter with robust financial performance, strategic product launches, and optimistic guidance updates. Despite facing FX challenges, the company remains well-positioned for growth through innovation and market expansion.

Abbott Labs excels in Q2, raises guidance amid strong segment performance

Abbott Labs' Q2 performance reflects strong growth momentum across segments and strategic focus on innovation and market expansion.
The company's strengths in Nutrition, Diagnostics, and Medical Devices position it well for sustained growth and value creation.
While facing challenges such as ongoing litigation, Abbott Labs remains poised to capitalize on opportunities in biosimilars, new product approvals, and market expansion.

Abbott Labs excels in Q3 with strong sales growth and strategic advancements

Abbott Labs demonstrated robust financial performance and strategic advancements in Q3 2024, showcasing resilience and innovation. While facing potential challenges ahead, the company's diverse portfolio and market-leading products position it well for future growth and success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.

Brokers Suggest Investing in Abbott (ABT): Read This Before Placing a Bet

Shares of Abbott Laboratories (ABT) came under pressure Monday after a jury in St. Louis late Friday ordered the company to pay $495 million in compensation and damages in a lawsuit over the company's specialized formula for premature babies.

Abbott Stock Slips After Company Ordered to Pay $495 Million in Baby Formula Case

Abbott Laboratories (NYSE:ABT)) is off 3.6% to trade at $101.44 this morning, suffering a drop after its premature infant formula trial ended in the company needing to pay $495 million in damages to those impacted by a possible increase in bowel disease.

Trial Defeat, Resistance Level Drags Abbott Stock

CVS Health

Devon Energy

Helen of Troy

Hershey

Interpublic Group of Companies

Lamb Weston Hlds

PepsiCo

STMicroelectronics NV ADR RegS

Zimmer Biomet Hlds

Here is my list of blue-chip stocks to research for a buy-on-weakness strategy. Each has the potential to dip by -10% to -20%, given the July S&P 500 correction expands into a more serious bear market. The goal is to purchase stocks at low future PEG Ratios and EV to EBITDA readings for +50% to +100% total returns by the end of 2025.

10 Beaten-Up Blue Chips With Serious Turnaround Potential

Abbott Labs (NYSE: ABT ) stock is falling more than 4% after a St. Louis jury found its premature infant baby formula responsible for a potentially fatal bowel disease. As of this writing, ABT stock is trading around the $100 mark.

Abbott Labs (ABT) Stock Falls on Baby Formula Ruling. What to Know.

AbbVie

Target

High-yield dividend stocks are attractive investment options as they provide regular payouts regardless of market performance. Understanding dividend yield, which is a ratio showing annual dividend income per dollar invested, is crucial for comparing investments.

3 High-Yield Dividend Stocks That Are Looking Super Hot

Integra LifeSciences Holdings

U.S. stock futures were higher this morning, with the Dow futures gaining around 150 points on Monday.

Abbott, Integra LifeSciences And Other Big Stocks Moving Lower In Monday's Pre-Market Session

Shares of Abbott Laboratories (NYSE:ABT) were marked 5% lower in pre-market trading after a Missouri jury awarded $495 million in a baby formula case. The case involved a child who developed necrotizing enterocolitis after consuming Similac, with the claim that Abbott failed to warn about the risks.

Abbott Laboratories down 5% premarket on baby formula verdict

Reckitt Benckiser Group PLC

Shares of Abbott Laboratories and U.K.-listed Reckitt Benckiser both drop after a Missouri jury rules against the American healthcare company.

Abbott Labs Stock Falls After Baby-Formula Ruling. Reckitt Benckiser Tumbles Too.

U.K. consumer-products giant Reckitt saw its share price slump after a jury awarded $495 million in a key baby-formula case.

Baby-formula settlement drags Reckitt down after $495 million jury award against Abbott

Abbott Laboratories' shares fell nearly 7% premarket, while British peer Reckitt Benckiser slumped 9% on Monday, after the U.S. healthcare firm was ordered to pay $495 million in damages related to its formula for premature infants.

Abbott shares slide after trial verdict, weigh on rival Reckitt Benckiser

A jury found that Abbott Laboratories' specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $495 million in damages.

Abbott must pay $495M in damages after girl develops dangerous disease from premature infant formula

A jury ordered Abbott Laboratories ABT -0.68%decrease; red down pointing triangle to pay $495 million in compensation and damages after determining that the company failed to warn that its formula for premature infants increased the risk for a bowel disease.

Abbott Ordered to Pay $495 Million in Baby-Formula Verdict

A jury on Friday found that Abbott Laboratories' specialized formula for premature infants caused an Illinois girl to develop a dangerous bowel disease, ordering the healthcare company to pay $95 million in compensatory damages.

Abbott must pay $95 million in premature infant formula trial, jury finds

Abbott (NYSE: ABT) recently reported its Q2 results, with revenues and earnings exceeding our expectations. The company reported revenue of $10.4 billion and earnings of $1.14 on a per-share and adjusted basis, compared to our estimates of $10.3 billion and $1.10, respectively.

Should You Pick Abbott Stock At $105 After A Solid Q2?

Intuitive Surgical

Healthcare stocks are generally good bets, thanks to a rapidly growing population of older adults in the U.S. and other developed economies. Abbott Laboratories is growing sales at a high-single-digit annual percentage and offers a quarterly dividend.

Better Buy: Abbott Laboratories vs. Intuitive Surgical

Home Depot

JPMorgan Chase & Co

Abbott's diverse business and low beta value make it one of the safest dividend stocks you can own. Home Depot doesn't expect much growth this year, but that likely won't remain a long-term problem.

3 High-Yielding Dividend Stocks That Can Help Bankroll Your Retirement Years

Amgen

Lowe's

Nordson

NIKE

Parker-Hannifin

S&P Global

Visa

These blue-chip companies have demonstrated strong dividend growth rates ranging from 7.69% to 15.8% annually over the past five years. The list includes diverse sectors such as retail, healthcare, technology, and finance, offering potential for portfolio diversification.

10 Best Dividend Growth Stocks to Buy and Hold Forever

Johnson Controls

McDonald's

Microsoft

Procter & Gamble

Public Storage

Waste Management

The concept of safe stocks arguably couldn't be timelier. Recently, the technology sector encountered significant turmoil, with many experts questioning the sustained success of artificial intelligence and related innovations.

7 Safe Stocks to Buy for Volatility Insurance

Shares of Abbott Laboratories (ABT) declined in intraday trading Thursday as the healthcare products maker's sales of COVID-19 tests slumped with the pandemic ending.

Abbott Laboratories Posts Big Drop in COVID-19 Testing Revenue

U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 100 points on Thursday.

Nasdaq Down Over 100 Points; Abbott Laboratories Earnings Beat Views

Abbott Laboratories will use a mix of TV advertisements and guerilla marketing as well as seek to personalize health data to tap people without diabetes for the U.S. launch of its glucose monitoring device, CEO Robert Ford said on Thursday.

Abbott plans marketing push for glucose monitors beyond diabetes

Abbott Laboratories (NYSE: ABT) faced a 3.0% decline in stock price this morning despite reporting a strong second quarter and raising its full-year guidance. Meanwhile, CEO Robert B.

Should you buy Abbott stock? CEO sees multi-billion dollar opportunity in new product

Abbott Laboratories (NYSE:ABT ) Q2 2024 Earnings Conference Call July 18, 2024 9:00 AM ET Company Participants Robert Ford - Chief Executive Officer Phil Boudreau - Executive Vice President, Finance, Chief Financial Officer Mike Comilla - Vice President, Investor Relations Conference Call Participants Larry Biegelsen - Wells Fargo Travis Sneed - Bank of America Robbie Marcus - JP Morgan Josh Jennings - TD Cowen David Roman - Goldman Sachs Danielle Antalffy - UBS Vijay Kumar - Evercore ISI Operator Good morning and thank you for standing by. Welcome to Abbott's second quarter 2024 earnings conference call.

Abbott Laboratories (ABT) Q2 2024 Earnings Call Transcript

Abbott (ABT) delivers a strong underlying base business performance in the second quarter of 2024.

News for Abbott Labs Stock (ABT)